Apollo, Zydus launch blood test for early detection of multiple cancers

Apollo Cancer Centres (ACCs) have launched a blood-based multi-cancer detection test in India, following an agreement with Zydus Lifesciences to offer the screening technology developed by Guardant Health.

The Shield™ Multi-Cancer Detection (MCD) test is a methylation-based blood test designed to detect signals associated with 10 cancer types: bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian, and pancreatic. It is intended for individuals aged 45 and above who are at average risk for cancer.

Apollo Hospitals stated that the test's introduction comes amid a rising cancer burden in the country. The test was launched by Harshad Reddy, director of group oncology at Apollo Hospitals; Simranjit Singh, chief executive officer of Guardant Health AMEA; and Keyur Parekh, president of BU Biologics and corporate strategy at Zydus Lifesciences.

Harit K. Chaturvedi, CEO and clinical head of oncology at Apollo Hospitals, noted that the test is a simple blood draw with strong sensitivity and specificity for certain cancers. However, he emphasised that no single test can yet serve as an ideal solution for early detection of all cancers, and the test should be used under professional medical guidance.

Mr Singh said the blood test could help identify cancer signals in a single draw, facilitating earlier clinical evaluation.

According to a press release, the test has received Breakthrough Device Designation from the U.S. Food and Drug Administration for eight cancer types. This designation does not constitute FDA approval or clearance. The Shield MCD test is a laboratory-developed test intended for export and is not approved for sale or use in the United States.